|
1
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: the avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010.PubMed/NCBI
|
|
2
|
Vescovi AL, Galli R and Reynolds BA: Brain
tumour stem cells. Nat Rev Cancer. 6:425–436. 2006. View Article : Google Scholar
|
|
3
|
Huang Q, Zhang QB, Dong J, Wu YY, Shen YT,
Zhao YD, Zhu YD, Diao Y, Wang AD and Lan Q: Glioma stem cells are
more aggressive in recurrent tumors with malignant progression than
in the primary tumor, and both can be maintained long-term in
vitro. BMC Cancer. 8:3042008. View Article : Google Scholar
|
|
4
|
He H, Li MW and Niu CS: The pathological
characteristics of glioma stem cell niches. J Clin Neurosci.
19:121–127. 2012. View Article : Google Scholar
|
|
5
|
Johannessen TC, Bjerkvig R and Tysnes BB:
DNA repair and cancer stem-like cells - potential partners in
glioma drug resistance? Cancer Treat Rev. 34:558–567. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang MK and Kang SK: Tumorigenesis of
chemotherapeutic drug-resistant cancer stem-like cells in brain
glioma. Stem Cells Dev. 16:837–847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Z, Bao S, Wu Q, Wang H, Eyler C,
Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al:
Hypoxia-inducible factors regulate tumorigenic capacity of glioma
stem cells. Cancer Cell. 15:501–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heddleston JM, Wu Q, Rivera M, Minhas S,
Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB and Rich JN:
Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell
tumorigenic potential. Cell Death Differ. 19:428–439. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soeda A, Park M, Lee D, Mintz A,
Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T,
Kassam AB, et al: Hypoxia promotes expansion of the CD133-positive
glioma stem cells through activation of HIF-1alpha. Oncogene.
28:3949–3959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kensler TW, Wakabayashi N and Biswal S:
Cell survival responses to environmental stresses via the
Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 47:89–116.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao F, Wu T, Lau A, Jiang T, Huang Z,
Wang XJ, Chen W, Wong PK and Zhang DD: Nrf2 promotes neuronal cell
differentiation. Free Radic Biol Med. 47:867–879. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kato K, Takahashi K, Monzen S, Yamamoto H,
Maruyama A, Itoh K and Kashiwakura I: Relationship between
radiosensitivity and Nrf2 target gene expression in human
hematopoietic stem cells. Radiat Res. 174:177–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bobilev I, Novik V, Levi I, Shpilberg O,
Levy J, Sharoni Y, Studzinski GP and Danilenko M: The Nrf2
transcription factor is a positive regulator of myeloid
differentiation of acute myeloid leukemia cells. Cancer Biol Ther.
11:317–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Y, Wang HD, Zhu L, Cong ZX, Li N, Ji
XJ, Pan H, Wang JW and Li WC: Knockdown of Nrf2 enhances autophagy
induced by temozolomide in U251 human glioma cell line. Oncol Rep.
29:394–400. 2013.PubMed/NCBI
|
|
16
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133(+) and CD133(−) glioblastoma-derived cancer stem cells
show differential growth characteristics and molecular profiles.
Cancer Res. 67:4010–4015. 2007.
|
|
17
|
Strojnik T, Røsland GV, Sakariassen PO,
Kavalar R and Lah T: Neural stem cell markers, nestin and musashi
proteins, in the progression of human glioma: correlation of nestin
with prognosis of patient survival. Surg Neurol. 68:133–144. 2007.
View Article : Google Scholar
|
|
18
|
Närvä E, Rahkonen N, Emani MR, Lund R,
Pursiheimo JP, Nästi J, Autio R, Rasool O, Denessiouk K, Lähdesmäki
H, et al: RNA-binding protein L1TD1 interacts with LIN28 via RNA
and is required for human embryonic stem cell self-renewal and
cancer cell proliferation. Stem Cells. 30:452–460. 2012.PubMed/NCBI
|
|
19
|
Sharma V, Dixit D, Ghosh S and Sen E:
COX-2 regulates the proliferation of glioma stem like cells.
Neurochem Int. 59:567–571. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mizrak D, Brittan M and Alison MR: CD133:
molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shmelkov SV, St Clair R, Lyden D and Rafii
S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Folkins C, Shaked Y, Man S, Tang T, Lee
CR, Zhu Z, Hoffman RM and Kerbel RS: Glioma tumor stem-like cells
promote tumor angiogenesis and vasculogenesis via vascular
endothelial growth factor and stromal-derived factor 1. Cancer Res.
69:7243–7251. 2009. View Article : Google Scholar
|
|
23
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
24
|
Kondo T, Setoguchi T and Taga T:
Persistence of a small subpopulation of cancer stem-like cells in
the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan H, Wang H, Zhu L, Wang X, Cong Z, Sun
K and Fan Y: The involvement of Nrf2-ARE pathway in regulation of
apoptosis in human glioblastoma cell U251. Neurol Res. 35:71–78.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alam J, Stewart D, Touchard C, et al:
Nrf2, a Cap’n’Collar transcription factor, regulates induction of
the heme oxygenase-1 gene. J Biol Chem. 274:26071–26078. 1999.
|
|
27
|
Fan H, Guo H, Zhang IY, Liu B, Luan L, Xu
S, Hou X, Liu W, Zhang R, Wang X and Pang Q: The different HMGA1
expression of total population of glioblastoma cell line U251 and
glioma stem cells isolated from U251. Brain Res. 1384:9–14. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang M, Song T, Yang L, Chen R, Wu L,
Yang Z and Fang J: Nestin and CD133: valuable stem cell-specific
markers for determining clinical outcome of glioma patients. J Exp
Clin Cancer Res. 27:852008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Motohashi H and Yamamoto M: Nrf2-Keap1
defines a physiologically important stress response mechanism.
Trends Mol Med. 10:549–557. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang L, Lin C, Wang L, Guo H and Wang X:
Hypoxia and hypoxia-inducible factors in glioblastoma multiforme
progression and therapeutic implications. Exp Cell Res.
318:2417–2426. 2012. View Article : Google Scholar : PubMed/NCBI
|
